You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞康醫藥(002589.SZ):2019年度擬計提商譽減值準備約22.4億元
格隆匯 02-21 18:53

格隆匯2月21日丨瑞康醫藥(002589.SZ)公佈,近年來,公司抓住政策和市場機遇,通過一系列的投資併購,加速打造全國性、綜合性的醫療器械直銷網絡,完善和拓展公司產業佈局。由於公司外延收購的近兩百家公司具有輕資產屬性,在合併時形成了較大金額的商譽。

受國內宏觀經濟下行壓力影響,結合行業政策變化及子公司實際經營情況等因素,公司根據證監會《會計監管風險提示第8號----商譽減值》及相關會計政策規定,對報告期內所有子公司的經營情況進行了全面估計。2019年度,公司部分子公司業績沒有完全達到預期,基於謹慎性原則,計提商譽減值準備。

基於謹慎性原則,2019年度預計對90餘個資產組計提商譽減值準備金額約為22.4億元,根據公司《2018年年度報告》,公司2018年末淨資產為113.06億元,商譽減值損失金額占上年末淨資產比例為19.81%,超過上年末淨資產的百分之十。最終商譽減值準備計提將由公司聘請的具備證券期貨從業資格的評估機構及審計機構進行評估和審計後確定。

上述重大損失事項將對公司利潤總額和淨利潤產生較大影響,但不會對公司的現金流產生任何影響,不會影響公司現有主業及後續年度的正常經營,不會對公司的償債能力產生重大影響。

針對該重大損失事項,公司全面梳理排查了財務管理相關制度,尤其對資產的期末計價制度進行了梳理和完善,後續將進一步強化內部監督檢查機制。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account